Pfizer (NYSE: PFE) Executives are Making Moves with Their SharesBy Carrie Williams
Following Anthony Maddaluna’s last PFE Sell transaction on November 04, 2016, the stock climbed by 2.4%. In addition to Anthony Maddaluna, 2 other PFE executives reported Sell trades in the last month.
Based on Pfizer’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $13.05 billion and quarterly net profit of $1.32 billion. In comparison, last year the company earned revenue of $12.09 billion and had a net profit of $2.13 billion. The company has a one year high of $37.39 and a one year low of $28.25. Currently, Pfizer has an average volume of 67.28M.
Based on 10 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $40.00, reflecting a -16.3% downside. Three different firms, including Rafferty Capital and Standpoint Research, currently also have a Sell rating on the stock.
In the last 30 days, insiders have sold $882.5K worth of PFE shares and purchased $3.67M worth of PFE shares. The insider sentiment on Pfizer has been positive according to 65 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.